2019年儿童肺动脉高压诊断与治疗共识声明更新:欧洲儿童肺血管疾病网络(EPPVDN),获AEPC、ESPR和ISHLT认可
欧洲儿童肺血管疾病网络(EPPVDN)基于2016年执行摘要更新了儿童肺动脉高压诊断与治疗共识。写作组检索PubMed/MEDLINE(1990-2018)并召开面对面及网络会议,10个专题工作组投票产生推荐,采用欧洲心脏病学会/美国心脏协会的推荐类别(COR)和证据水平(LOE)定义,仅基于儿童数据或包含>10%儿童或成人先天性心脏病的研究。共识纳入2018年世界肺动脉高压研讨会新定义,生成10张分级推荐表,涵盖诊断/监测、遗传/生物标志物、心导管、超声心动图、心脏磁共振/胸部CT、相关类型肺动脉高压、ICU/肺移植及治疗,并首次制定中低收入地区肺动脉高压管理具体推荐。
要点
- 推荐采用欧洲心脏病学会/美国心脏协会的COR/LOE分级体系,仅基于儿童数据或含>10%儿童或成人先天性心脏病的研究进行分级。
- 共识纳入2018年世界肺动脉高压研讨会新定义,涵盖支气管肺发育不良相关、先天性心脏病相关、新生儿持续性肺动脉高压等儿童肺高压类型。
- 10张分级推荐表覆盖诊断/监测、遗传/生物标志物、心导管、超声心动图、心脏磁共振/胸部CT、相关类型、ICU/肺移植及治疗。
- 首次制定中低收入地区儿童肺动脉高压管理的具体推荐。
- 共识为儿童及年轻成人肺动脉高压的最佳临床管理提供具体、全面、详细且实用的框架。
适用人群与场景
- 儿童及年轻成人肺动脉高压患者,包括支气管肺发育不良相关肺高压、先天性心脏病相关肺高压、新生儿持续性肺高压及相关心脏功能障碍。
- 推荐分级基于儿童数据,或包含>10%儿童的研究,或纳入成人先天性心脏病的研究。
研究设计与关键结果
- 欧洲儿童肺血管疾病网络(EPPVDN)基于2016年执行摘要更新共识,写作组检索PubMed/MEDLINE(1990-2018)并召开面对面及网络会议,10个专题工作组投票产生推荐。
- 采用欧洲心脏病学会/美国心脏协会的推荐类别(COR)和证据水平(LOE)定义,仅基于儿童数据或包含>10%儿童的研究或纳入成人先天性心脏病的研究进行分级。
- 共识纳入2018年世界肺动脉高压研讨会新定义,生成10张分级推荐表,涵盖诊断/监测、遗传/生物标志物、心导管、超声心动图、心脏磁共振/胸部CT、相关类型肺高压、ICU/肺移植及治疗。
- 首次制定中低收入地区儿童肺动脉高压管理的具体推荐。
证据类型、等级与局限
- 证据类型:共识声明/指南,采用欧洲心脏病学会/美国心脏协会的COR/LOE分级体系。
- 局限:原文未报告局限性
对床旁实践的改变
- 共识为儿童及年轻成人肺动脉高压的最佳临床管理提供具体、全面、详细且实用的框架。
- 首次制定中低收入地区儿童肺动脉高压管理的具体推荐,适用于该地区临床实践。
指南或共识出处
- 2019年儿童肺动脉高压诊断与治疗共识声明更新:欧洲儿童肺血管疾病网络(EPPVDN),获AEPC、ESPR和ISHLT认可。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The European Pediatric Pulmonary Vascular Disease Network is a registered, non-profit organization that strives to define and develop effective, innovative diagnostic methods and treatment options in all forms of pediatric pulmonary hypertensive vascular disease, including pulmonary hypertension (PH) associated with bronchopulmonary dysplasia, PH associated with congenital heart disease (CHD), persistent PH of the newborn, and related cardiac dysfunction. The executive writing group members conducted searches of the PubMed/MEDLINE bibliographic database (1990-2018) and held face-to-face and web-based meetings. Ten section task forces voted on the updated recommendations, based on the 2016 executive summary. Clinical trials, meta-analyses, guidelines, and other articles that include pediatric data were searched using the term "pulmonary hypertension" and other keywords. Class of recommendation (COR) and level of evidence (LOE) were assigned based on European Society of Cardiology/American Heart Association definitions and on pediatric data only, or on adult studies that included >10% children or studies that enrolled adults with CHD. New definitions by the World Symposium on Pulmonary Hypertension 2018 were included. We generated 10 tables with graded recommendations (COR/LOE). The topics include diagnosis/monitoring, genetics/biomarkers, cardiac catheterization, echocardiography, cardiac magnetic resonance/chest computed tomography, associated forms of PH, intensive care unit/lung transplantation, and treatment of pediatric PH. For the first time, a set of specific recommendations on the management of PH in middle- and low-income regions was developed. Taken together, these executive, up-to-date guidelines provide a specific, comprehensive, detailed but practical framework for the optimal clinical care of children and young adults with PH.
参考来源
- Hansmann G, Koestenberger M, Alastalo TP, et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant. 2019. PMID: 31495407. doi:10.1016/j.healun.2019.06.022
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。